Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 3:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Akros Pharma Inc. Clear all
Completed Phase 2 Interventional

Safety Study of JTT-302 in Subjects With Low HDL-C Levels

NCT00748852
View directory record Official record
Conditions
Dyslipidemia
Interventions
JTT-302
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Santa Ana, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 4, 2026, 3:05 PM EDT
Completed Phase 1 Interventional

Effect of Hemodialysis on the PK of JTZ-951 in Subjects With End-stage Renal Disease

NCT01978587
View directory record Official record
Conditions
Anemia in Chronic Kidney Disease
Interventions
JTZ-951
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Oct 4, 2026, 3:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Safety, Tolerability and Pharmacokinetics of Single Oral JTT-251 Doses in Healthy and Type 2 Diabetic Subjects

NCT02106585
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
JTT-251 or Placebo
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 7, 2014 · Synced Oct 4, 2026, 3:05 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of JTT-302 in Subjects With Low HDL-C Levels

NCT00749788
View directory record Official record
Conditions
Dyslipidemia
Interventions
JTT-302, Placebo
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Santa Ana, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 4, 2026, 3:05 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of JTT-130 in Obese Type 2 Diabetic Patients

NCT00929539
View directory record Official record
Conditions
Type II Diabetes Mellitus
Interventions
JTT-130, JTT-130 Placebo
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
48
States / cities
Birmingham, Alabama • Muscle Shoals, Alabama • Scottsboro, Alabama + 45 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 4, 2026, 3:05 PM EDT
Completed Phase 1 Interventional

Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease

NCT02581124
View directory record Official record
Conditions
Anemia of Chronic Kidney Disease
Interventions
JTZ-951, Lapatinib
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 28, 2016 · Synced Oct 4, 2026, 3:05 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of JTT-252

NCT02120976
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
JTT-252 or Placebo, JTT-252
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Overland Park, Kansas • Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2015 · Synced Oct 4, 2026, 3:05 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Efficacy, Safety and Tolerability of JTE-051 in Subjects With Active Rheumatoid Arthritis

NCT02919475
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
JTE-051, Placebo
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
4
States / cities
Tucson, Arizona • Upland, California • Clearwater, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 4, 2026, 3:05 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus

NCT01699737
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
JTT-851, Glimepiride, Placebo for Active, Placebo for comparator
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
79
States / cities
Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 76 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2013 · Synced Oct 4, 2026, 3:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics Study Assessing Ascending Single Oral JTK-853 Doses in Healthy Subjects

NCT01475981
View directory record Official record
Conditions
Healthy
Interventions
JTK-853 or Placebo
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 22, 2011 · Synced Oct 4, 2026, 3:05 PM EDT
Completed Phase 1 Interventional

Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease

NCT01971164
View directory record Official record
Conditions
Anemia of Chronic Kidney Disease
Interventions
JTZ-951, Placebo
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
5
States / cities
Lakewood, Colorado • Miami, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Oct 4, 2026, 3:05 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis

NCT03832738
View directory record Official record
Conditions
Plaque Psoriasis, Psoriasis, Skin Diseases
Interventions
JTE-451 Tablets, Placebo Tablets
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Santa Monica, California • Temecula, California • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2021 · Synced Oct 4, 2026, 3:05 PM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTT-662 in Subjects With Type 2 Diabetes

NCT04465877
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
JTT-662, Placebo
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 27, 2023 · Synced Oct 4, 2026, 3:05 PM EDT
Completed Phase 1 Interventional

Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis

NCT02805244
View directory record Official record
Conditions
Anemia of Chronic Kidney Disease
Interventions
JTZ-951, 14C-JTZ-951
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Oct 4, 2026, 3:05 PM EDT
Completed Phase 2 Interventional

Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction

NCT06017609
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
JTT-861 Capsules, Placebo Capsules
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
30 Years to 85 Years
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
20
States / cities
Phoenix, Arizona • Crystal River, Florida • Hialeah, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 4, 2026, 3:05 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Two Week Study Evaluating Safety, Tolerability and Pharmacokinetics of Multiple Doses of JTK-853 in Healthy Subjects

NCT01473069
View directory record Official record
Conditions
Healthy
Interventions
JTK-853, ketoconazole, JTK-853 or Placebo
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2011 · Synced Oct 4, 2026, 3:05 PM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis

NCT03358290
View directory record Official record
Conditions
Plaque Psoriasis, Skin Diseases
Interventions
JTE-051, Placebo
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
12
States / cities
Fountain Valley, California • Fremont, California • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2021 · Synced Oct 4, 2026, 3:05 PM EDT
Terminated Phase 2 Interventional

Efficacy and Safety Study of JTT-654 in Type 2 Diabetic Patients

NCT00997152
View directory record Official record
Conditions
Type II Diabetes Mellitus
Interventions
JTT-654, JTT-654 Placebo
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
42
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 4, 2026, 3:05 PM EDT